Travere Therapeutics, Inc.

The Company's diluted earnings/(loss) per share computation includes the effect, if any, of shares that would be issuable upon the exercise of outstanding stock options, convertible debt and RSUs using the treasury stock method.

SEC original ↗Travere Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

In accordance with ASC 260, Earnings per Share , if a company had a discontinued operation, the company uses income from continuing operations, adjusted for preferred dividend and similar adjustments, as its control number to determine whether potential common shares are dilutive.

SEC original ↗Travere Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

2024-04, Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debts Instruments.

SEC original ↗Travere Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

This ASU clarifies the requirements for determining whether to account for certain early settlements of convertible debt instruments as induced conversions or extinguishments.

SEC original ↗Travere Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

See Note 10 for further discussion of accounting for convertible debt transactions during 2026.

SEC original ↗Travere Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

We continue to make strong progress against our strategic priorities, putting Travere on a trajectory for both near- and long-term growth.

SEC original ↗Travere Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

In addition, expressions of strategies, intentions or plans are also forward-looking statements.

SEC original ↗Travere Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Our future prospects are highly dependent upon our ability to successfully develop and execute commercialization strategies for our products, including FILSPARI, and to attain market acceptance among physicians, patients and healthcare payers.

SEC original ↗Travere Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Healthcare reform initiatives, unfavorable pricing regulations, and changes in reimbursement practices of third-party payers or patients' access to insurance coverage could affect the pricing of and demand for our products.

SEC original ↗Travere Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Travere is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases.

SEC original ↗Travere Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations.

SEC original ↗Travere Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties related to the Company s sNDA for FILSPARI in FSGS, including the timing and outcome thereof.

SEC original ↗Travere Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

The Company also faces risks and uncertainties related to its business and finances in general, the success of its commercial products, risks and uncertainties associated with its preclinical and clinical stage pipeline, risks and uncertainties associated with the regulatory review and approval process, risks and uncertainties associated with enrollment of clinical trials for rare diseases, and risks that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons.

SEC original ↗Travere Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Investors are referred to the full discussion of risks and uncertainties, including under the heading Risk Factors , as included in the Company s most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission.

SEC original ↗Travere Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Legal Proceedings 37 Item 1A.

SEC original ↗Travere Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements.

SEC original ↗Travere Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026